243 related articles for article (PubMed ID: 14664471)
21. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
[TBL] [Abstract][Full Text] [Related]
22. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.
Rovaris M; Comi G; Rocca MA; Wolinsky JS; Filippi M;
Brain; 2001 Sep; 124(Pt 9):1803-12. PubMed ID: 11522582
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
[TBL] [Abstract][Full Text] [Related]
24. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.
Ge Y; Grossman RI; Udupa JK; Fulton J; Constantinescu CS; Gonzales-Scarano F; Babb JS; Mannon LJ; Kolson DL; Cohen JA
Neurology; 2000 Feb; 54(4):813-7. PubMed ID: 10690968
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow up of glatiramer acetate compassionate use in Belgium.
Sindic CJ; Seeldrayers P; Vande Gaer L; De Smet E; Nagels G; De Deyn PP; Medaer R; Guillaume D; D'Hooghe MB; Deville MC; Decoo D; Sadzot B; Van Landegem W; Strauven T; Pepin J; Merckx H; Caekebeke J; van der Tool MA
Acta Neurol Belg; 2005 Jun; 105(2):81-5. PubMed ID: 16076061
[TBL] [Abstract][Full Text] [Related]
26. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
27. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
28. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
30. Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Harrison DM; Gladstone DE; Hammond E; Cheng J; Jones RJ; Brodsky RA; Kerr D; McArthur JC; Kaplin A
Mult Scler; 2012 Feb; 18(2):202-9. PubMed ID: 21865410
[TBL] [Abstract][Full Text] [Related]
31. Therapy with glatiramer acetate for multiple sclerosis.
Munari L; Lovati R; Boiko A
Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
[TBL] [Abstract][Full Text] [Related]
32. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
33. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
34. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients.
Vallittu AM; Peltoniemi J; Elovaara I; Kuusisto H; Färkkilä M; Multanen J; Erälinna JP
Acta Neurol Scand; 2005 Oct; 112(4):234-7. PubMed ID: 16146492
[TBL] [Abstract][Full Text] [Related]
36. The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis.
Singhal T; Tauhid S; Hurwitz S; Neema M; Bakshi R
J Neuroimaging; 2017 Jan; 27(1):33-36. PubMed ID: 27466943
[TBL] [Abstract][Full Text] [Related]
37. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
[TBL] [Abstract][Full Text] [Related]
38. Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
Qizilbash N; Mendez I; Sanchez-de la Rosa R
Clin Ther; 2012 Jan; 34(1):159-176.e5. PubMed ID: 22284996
[TBL] [Abstract][Full Text] [Related]
39. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Hawkins C;
J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
